NL-OMON35795撤回2 期
A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylaat Administered with Ribavirin - ANA773 with ribavirin in chronic hepatitis C infected subjects
Anadys Therapeutics Inc.0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Hepatitis C, genotype 1
- •IL28B genotypic polymorphism CT
- •naïve to or have relapsed from prior pegylated interferon-alpha based therapy
- •Age between 18 - 65 year of each
排除标准
- •Pregnant or lactating females;
- •patient previously treated with experimental drugs for HCV
研究者
相似试验
进行中（未招募）
不适用
A clinical investigation in the early stages of drug development to evaluate the safety and tolerability of a new drug for the treatment of hepatitis C when it is given to hepatitis C patients together with ribavirin.Chronic Hepatitis C Viral InfectionMedDRA version: 13.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-000728-14-NLAnadys Development, LTD40
进行中（未招募）
1 期
A Phase II/III Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine (Menveo) or Glaxosmithkline Meningococcal ACWY Conjugate Vaccine in Adolescents Who Were Primed with Meningitec, Menjugate or Neisvac-C During Preschool Vaccination - PRIMEThese vaccines are intended for the prevention of infection by meningococcal serogroups A,C,W135 and Y.EUCTR2010-022505-18-GBHealth Protection Agency93
未知
2 期
ShineGastric CancerJPRN-jRCT2080221961AstraZeneca
进行中（未招募）
不适用
Efficacy and safety of AZD4547 versus paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer patientsEUCTR2010-023377-19-BEAstraZeneca240
进行中（未招募）
不适用
Efficacy and safety of AZD4547 versus paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer patientsFGFR, Amplification, polysomy, gastro-oesophageal junction cancer, lower third oesophageal cancer, gastric cancer, randomised, efficacyMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061967Term: Gastric cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10030159Term: Oesophageal carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10017765Term: Gastric cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10026104Term: Malignant neoplasm of lower third of esophagusSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10030155Term: Oesophageal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023377-19-BGAstraZeneca240